companies / itm-rp-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-22 json
| total_raised | 378,000,000378.0M | ○ |
|---|---|---|
| founded | 2011 | |
| hq | Munich, Germany | |
| industry | unknown | |
| stage | series-b+ |
ITM Radiopharma develops, manufactures, and supplies targeted radiopharmaceuticals including ITM-11 (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors. It treats patients with NETs, glioblastoma, osteosarcoma, and folate-receptor cancers. ITM runs its own GMP isotope production and beat Afinitor in Phase III.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-06-01 | strategic | 203,040,000203.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Strategic, $203.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |